Next Article in Journal
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
Previous Article in Journal
Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
Previous Article in Special Issue
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessEditorial
Cancers 2017, 9(11), 150;

CAR-T Cell Therapy: From the Bench to the Bedside

Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
Academic Editor: Samuel C. Mok
Received: 27 October 2017 / Revised: 30 October 2017 / Accepted: 30 October 2017 / Published: 31 October 2017
(This article belongs to the Special Issue CAR-T Cell Therapy against Different Types of Cancer)
Full-Text   |   PDF [152 KB, uploaded 31 October 2017]
Note: In lieu of an abstract, this is an excerpt from the first page.


CAR (Chimeric Antigen receptor)-T cell therapy is a novel type of therapy that uses engineered T cells with an antibody single-chain variable fragment (ScFv) extracellular domain that binds tumor-associated antigens[...] View Full-Text
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Golubovskaya, V. CAR-T Cell Therapy: From the Bench to the Bedside. Cancers 2017, 9, 150.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top